At the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, Dr. Yelena Janjigian discussed the results of the phase 3 MATTERHORN study, which analyzed pCR to FLOT with or without durvalumab in patients with resectable gastric and gastroesophageal junction cancers.
Catch up on more ASCO #GI24 coverage here: [ Ссылка ]

свернуть